公司名稱: 奧星生命科技有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06118 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法定/ ...

Core Viewpoint - Aoxing Life Science Technology (06118.HK) reported a decrease in revenue for the first half of 2025, but significant growth in net profit and order intake, indicating resilience in key projects and operational efficiency [1] Financial Performance - Revenue for the first half of 2025 was RMB 662 million, a decrease of 5.57% year-on-year [1] - Profit attributable to owners increased to RMB 24.999 million, a year-on-year growth of 325.37% [1] - Basic earnings per share were RMB 0.05 [1] Order and Project Performance - Total order amount for the first half of 2025 was approximately RMB 1.0418 billion, an increase of about RMB 135.7 million or 15.0% year-on-year [1] - The integrated process and packaging equipment systems business saw a significant growth of 32.3% [1] - Consulting, digitalization, and construction business segments also experienced a growth of 4.2% [1] Cash Flow and Profitability - Net profit after tax showed a significant increase compared to the same period in 2024 [1] - Operating cash flow increased by over 99% compared to 2024 [1]

Core Viewpoint - Aoxing Life Science Technology (06118) reported a decrease in revenue for the six months ending June 30, 2025, while showing a significant increase in net profit attributable to shareholders [1] Financial Performance - Revenue for the period was 662 million RMB, representing a year-on-year decrease of 5.57% [1] - Net profit attributable to shareholders was 24.999 million RMB, which is a substantial increase of 325.37% compared to the previous year [1] - Basic earnings per share were reported at 0.05 RMB [1]

Group 1 - The company, Aoxing Life Science Technology (06118), reported a revenue of 662 million RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 5.57% [1] - The net profit attributable to shareholders was 24.999 million RMB, showing a significant year-on-year increase of 325.37% [1] - The basic earnings per share were reported at 0.05 RMB [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 奧星生命科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：6118） Austar Lifesciences Limited 截至2025年6月30日止六個月之 中期業績公告 | 本集團財務摘要 | | | | | --- | --- | --- | --- | | | 截至6月30日止六個月 | | | | | | 2025年 | 2024年 | | | | 人民幣千元 | 人民幣千元 | | | | （未經審核） | （未經審核） | | 收入 | | 661,905 | 700,919 | | 毛利 | | 139,143 | 145,417 | | 除所得稅前溢利 | | 30,303 | 9,186 | | 本公司擁有人應佔溢利 | | 24,999 | 5,877 | | 毛利率 | | 21.0% | 20.7% | | （附註） 每股基本盈利 | | ...

Group 1 - The company announced the resignation of Mr. Chen Yuewu as an executive director and member of the risk management committee, effective from August 26, 2025 [1] - Mr. Bian Ce has been appointed as the executive director and member of the risk management committee, effective from the same date to succeed Mr. Chen [1]

Core Viewpoint - Aoxin Life Technology (06118.HK) announced the resignation of Chen Yuewu as an executive director and member of the board's risk management committee, effective August 26, 2025. The board appointed Bian Ce to replace Chen in both roles starting from the same date [1]. Group 1 - Chen Yuewu has resigned due to other work commitments [1] - Bian Ce has been appointed as the new executive director and risk management committee member [1] - The changes in the board are effective from August 26, 2025 [1]

Core Viewpoint - Aoxin Life Technology (06118) announced the resignation of Mr. Chen Yuewu as an executive director and member of the board's risk management committee, effective from August 26, 2025. Mr. Bian Ce has been appointed as the new executive director and member of the risk management committee to succeed Mr. Chen [1]. Group 1 - Mr. Chen Yuewu has resigned due to other work commitments [1] - Mr. Bian Ce will take over the role of executive director and risk management committee member [1] - The changes in the board are set to take effect on August 26, 2025 [1]

Austar Lifesciences Limited 奧星生命科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （ 股份代號︰ 6118） 董事名單以及彼等之角色和職能 奧星 生 命科 技 有限 公司 之 董事 （「董 事 」） 會（「董事會 」） 成員 （ 自 2025 年 8 月 26 日起 生 效） 載 列 如下 ： 執行董事 何國 強 先生 （ 主席 兼行 政 總裁 ） 何建 紅 先生 周寧 女 士 邊策 先 生 非執行董事 季玲 玲 女士 獨 立 非 執 行 董事 張立 基 先生 趙凱 珊 女士 梁愷 健 先生 董事 會 設有 五 個董 事會 委 員會。下 表 載列 各 委員 會 內董 事會 成 員之資料（ 自 2025 年 8 月 26 日起 生 效 ）。 | 委員會 | | | | 企 業 | 風 險 | | --- | --- | --- | --- | --- | --- | | | 審 核 | 薪 酬 | 提 名 | 管 治 | 管 理 | | 董 事 | 委員會 | 委員會 | 委員會 | 委員會 | 委 員 會 | | 何國 強 先生 | | | C | ...

執行董事變更及 董事委員會組成變更 執行董事辭任 Austar Lifesciences Limited 奧星生命科技有限公司 （於開曼群島註冊成立之有限公司） （股份代號︰6118） 陳先生已確認彼與董事會之間並無意見分歧，且就彼辭任一事並無事項需提請本 公司股東（「股東」）垂注。 董事會謹此衷心感謝陳先生於任職期間為本集團作出的寶貴貢獻。 委任執行董事 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 奧星生命科技有限公司（「本公司」，連同其附屬公司，「本集團」）之董事（「董 事」）會（「董事會」）宣佈，陳躍武先生（「陳先生」）因其他工作安排，已辭任執 行董事職務，並不再擔任董事會風險管理委員會（「風險管理委員會」）成員，自 2025 年 8 月 26 日（「生效日期」）起生效。 - 2 - 除本公告所披露者外，於本公告日期，邊先生(i) 於過往三年內並無出任任何其他 於香港或海外上市公司的任何董事職務；(ii) 並無任何其他主要任命及專業資格； ( ...